{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:07:18Z","timestamp":1792516038502,"version":"4.5.0"},"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Negative symptoms of schizophrenia are a range of deficits or losses in mental functioning associated with the disorder, including blunted affect, alogia, avolition, asociality, and anhedonia. These symptoms severely impact the quality of life of patients and hinder the recovery process. They significantly impair patients\u2019 ability to live independently, maintain social relationships, and function effectively in society. However, current treatments for negative symptoms of schizophrenia are limited in efficacy and remain controversial. Cognitive-behavioral therapy (CBT) is a goal-oriented psychotherapy that aims to improve individuals\u2019 emotional and psychological states by changing their negative thought patterns and behaviors. It helps patients identify and challenge irrational beliefs while promoting more positive behavioral changes through behavioral experiments and skills training. This study aims to conduct a meta-analysis to assess the effects of CBT on negative symptoms and function in schizophrenia.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objectives<\/jats:title>\n<jats:p>This study aimed to investigate the effects of cognitive behavioral therapy on negative symptoms, mental function, social skills, and social functioning in schizophrenia.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Literature was retrieved from 10 databases (PubMed, EMBASE, Cochrane Library, Web of Science, APA PsycINFO, CINAHL, MEDLINE, CNKI, Wan fang Database and SinoMed,), with the search period ranging from the inception date to 1 September 2024. Two researchers independently conducted a literature review, data extraction, and risk of bias assessment. The quality of the included studies was assessed using the Cochrane Risk of Bias tool, and the meta-analysis was conducted using RevMan 5.3. The measurement outcomes include negative symptoms of schizophrenia, overall function, social skills, and social functioning.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Result<\/jats:title>\n<jats:p>The analysis included a total of 15 studies involving 1,311 participants. All studies used the Positive and Negative Syndrome Scale (PANSS) as the assessment tool for measuring negative symptoms of schizophrenia. The results of the meta-analysis indicated that cognitive-behavioral therapy (CBT) significantly improved negative symptoms in patients with schizophrenia compared to treatment as usual (TAU) (MD\u2009=\u2009-1.65, 95% CI\u2009=\u2009-2.10 to -1.21, p\u2009&lt;\u20090.001, I\u00b2\u2009=\u200941%). Short-term CBT significantly improved negative symptoms in schizophrenia (MD\u2009=\u2009-2.71, 95% CI\u2009=\u2009-3.18 to -1.61, p\u2009&lt;\u20090.001, I\u00b2\u2009=\u200948%). Medium-term CBT also significantly improved negative symptoms (MD\u2009=\u2009-1.80, 95% CI\u2009=\u2009-2.76 to -0.84, p\u2009&lt;\u20090.001, I\u00b2\u2009=\u200929%). Long-term CBT demonstrated significant improvement in negative symptoms as well (MD\u2009=\u2009-1.70, 95% CI\u2009=\u2009-2.54 to -0.85, p\u2009&lt;\u20090.001, I\u00b2\u2009=\u20090%). CBT significantly improved overall function in patients with schizophrenia (SMD\u2009=\u20090.38, 95% CI\u2009=\u20090.13 to 0.63, p\u2009&lt;\u20090.05, I\u00b2\u2009=\u20090%). Additionally, CBT significantly enhanced social skills (SMD\u2009=\u20090.87, 95% CI\u2009=\u20090.58 to 1.16, p\u2009&lt;\u20090.001, I\u00b2\u2009=\u20090%) and social functioning (SMD\u2009=\u20090.19, 95% CI\u2009=\u20090.03 to 0.36, p\u2009&lt;\u20090.05, I\u00b2\u2009=\u200924%) in these patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The results indicate that cognitive behavioral therapy has a significant effect on improving the negative symptoms of schizophrenia and is markedly superior to Treatment as Usual (TAU). Moreover, all three sub-treatment approaches (short-term, medium-term, and long-term) can sustainably and significantly improve negative symptoms of schizophrenia. Future research should focus on developing and evaluating cognitive therapies targeting negative symptoms, providing more reliable evidence and applying these research findings to clinical practice.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0324685","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T17:58:19Z","timestamp":1747763899000},"page":"e0324685","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cognitive-behavioral therapy for the improvement of negative symptoms and functioning in schizophrenia: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4812-1046","authenticated-orcid":true,"given":"Yu","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinglin","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"pone.0324685.ref001","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2004.01.009","article-title":"Cognitive functioning, symptoms, and work in supported employment: a review and heuristic model","volume":"70","author":"SR McGurk","year":"2004","journal-title":"Schizophr Res"},{"issue":"10053","key":"pone.0324685.ref002","first-page":"1603","article-title":"Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet (London, England","volume":"388","year":"2016"},{"issue":"2","key":"pone.0324685.ref003","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms","volume":"32","author":"B Kirkpatrick","year":"2006","journal-title":"Schizophr Bull"},{"issue":"4","key":"pone.0324685.ref004","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/schbul\/sby169","article-title":"Reconsidering the latent structure of negative symptoms in schizophrenia: a review of evidence supporting the 5 consensus domains","volume":"45","author":"GP Strauss","year":"2019","journal-title":"Schizophr Bull"},{"issue":"4","key":"pone.0324685.ref005","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3390\/jcm11040983","article-title":"Impact of negative symptoms on functioning and quality of life in first psychotic episodes of schizophrenia","volume":"11","author":"L Garc\u00eda-Fern\u00e1ndez","year":"2022","journal-title":"J Clin Med"},{"issue":"7","key":"pone.0324685.ref006","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2015.09.351","article-title":"Impact of negative symptoms on quality of life in patients with schizophrenia","volume":"18","author":"D Novick","year":"2015","journal-title":"Value Health"},{"issue":"4","key":"pone.0324685.ref007","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/schbul\/sbu170","article-title":"Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials","volume":"41","author":"P Fusar-Poli","year":"2015","journal-title":"Schizophr Bull"},{"issue":"7","key":"pone.0324685.ref008","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00406-018-0869-3","article-title":"Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis","volume":"268","author":"M Krause","year":"2018","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"pone.0324685.ref009","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40501-016-0075-8","article-title":"Treating negative symptoms in schizophrenia: an update","volume":"3","author":"G Remington","year":"2016","journal-title":"Curr Treat Options Psychiatry"},{"issue":"3","key":"pone.0324685.ref010","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/npr2.12193","article-title":"Guideline for pharmacological therapy of schizophrenia","volume":"41","author":"Japanese Society of Neuropsychopharmacology","year":"2021","journal-title":"Neuropsychopharmacol Rep. 2021"},{"issue":"1","key":"pone.0324685.ref011","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/schbul\/sbp115","article-title":"The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements","volume":"36","author":"LB Dixon","year":"2010","journal-title":"Schizophr Bull"},{"issue":"2","key":"pone.0324685.ref012","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1682\/JRRD.2004.02.0225","article-title":"Attributional style and symptoms as predictors of social function in schizophrenia","volume":"41","author":"PH Lysaker","year":"2004","journal-title":"J Rehabil Res Dev"},{"issue":"3","key":"pone.0324685.ref013","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/schbul\/sbm114","article-title":"Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor","volume":"34","author":"T Wykes","year":"2008","journal-title":"Schizophr Bull"},{"issue":"1","key":"pone.0324685.ref014","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/s12888-018-1964-8","article-title":"Response rates in patients with schizophrenia and positive symptoms receiving cognitive behavioural therapy: a systematic review and single-group meta-analysis","volume":"18","author":"I Bighelli","year":"2018","journal-title":"BMC Psychiatry"},{"issue":"3","key":"pone.0324685.ref015","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019280","article-title":"Psychological interventions for positive symptoms in schizophrenia: protocol for a network meta-analysis of randomised controlled trials","volume":"8","author":"I Bighelli","year":"2018","journal-title":"BMJ Open"},{"issue":"36","key":"pone.0324685.ref016","article-title":"Cognitive-behavioral therapy for negative symptoms of schizophrenia: a systematic review and meta-analysis","volume":"103","author":"F Xu","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"pone.0324685.ref017","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"D Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"pone.0324685.ref018","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/9780470712184.ch5","article-title":"Defining the review question and developing criteria for including studies.","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"D O\u2019Connor","year":"2008"},{"key":"pone.0324685.ref019","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"JPT Higgins","year":"2011","journal-title":"BMJ"},{"issue":"7109","key":"pone.0324685.ref020","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"M Egger","year":"1997","journal-title":"BMJ"},{"issue":"7651","key":"pone.0324685.ref021","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \u201cquality of evidence\u201d and why is it important to clinicians?","volume":"336","author":"GH Guyatt","year":"2008","journal-title":"BMJ"},{"key":"pone.0324685.ref022","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"J Chandler","year":"2019"},{"key":"pone.0324685.ref023","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1192\/bjp.bp.106.021386","article-title":"Group cognitive-behavioural therapy for schizophrenia. Randomised controlled trial","volume":"189","author":"C Barrowclough","year":"2006","journal-title":"Br J Psychiatry"},{"key":"pone.0324685.ref024","doi-asserted-by":"crossref","DOI":"10.1016\/S0920-9964(14)70242-7","article-title":"Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic medication: a randomised controlled trial","volume":"153","author":"AP Morrison","year":"2014","journal-title":"Schizophrenia Res"},{"key":"pone.0324685.ref025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-9964(02)00308-0","article-title":"Cognitive therapy for schizophrenia: a preliminary randomized controlled trial","volume":"63","author":"NA Rector","year":"2003","journal-title":"Schizophr Res"},{"key":"pone.0324685.ref026","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.schres.2010.08.006","article-title":"A pilot investigation of the Graduated Recovery Intervention Program (GRIP) for first episode psychosis","volume":"125","author":"DL Penn","year":"2011","journal-title":"Schizophr Res"},{"issue":"3","key":"pone.0324685.ref027","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1017\/S0033291703007323","article-title":"Early intervention for relapse in schizophrenia: results of a 12-month randomized controlled trial of cognitive behavioural therapy","volume":"33","author":"A Gumley","year":"2003","journal-title":"Psychol Med"},{"issue":"7","key":"pone.0324685.ref028","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00787-019-01415-4","article-title":"Cognitive behavioral therapy in adolescents with early-onset psychosis: a randomized controlled pilot study","volume":"29","author":"H M\u00fcller","year":"2020","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"pone.0324685.ref029","doi-asserted-by":"crossref","first-page":"152157","DOI":"10.1016\/j.comppsych.2019.152157","article-title":"Cognitive behavior therapy in early psychosis with a focus on depression and low self-esteem: a randomized controlled trial","volume":"97","author":"N S\u00f6nmez","year":"2020","journal-title":"Compr Psychiatry"},{"issue":"4","key":"pone.0324685.ref030","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1600-0447.2010.01572.x","article-title":"A randomised controlled trial of cognitive behaviour therapy for psychosis in a routine clinical service","volume":"122","author":"E Peters","year":"2010","journal-title":"Acta Psychiatr Scand"},{"key":"pone.0324685.ref031","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1192\/bjp.184.3.231","article-title":"Cognitive-behavioural therapy in first-episode and early schizophrenia. 18-month follow-up of a randomised controlled trial","volume":"184","author":"N Tarrier","year":"2004","journal-title":"Br J Psychiatry"},{"issue":"8","key":"pone.0324685.ref032","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S2215-0366(18)30184-6","article-title":"Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial","volume":"5","author":"AP Morrison","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"pone.0324685.ref033","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S2215-0366(18)30096-8","article-title":"Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study","volume":"5","author":"AP Morrison","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"10","key":"pone.0324685.ref034","first-page":"116","article-title":"Analyzing the effects of cognitive behavioral therapy in schizophrenic patients with depressive symptoms","volume":"19","author":"J Yan","year":"2024","journal-title":"Psychol Month"},{"issue":"04","key":"pone.0324685.ref035","first-page":"126","article-title":"Effects of psychological care based on cognitive behavioral therapy on patients with schizophrenia","volume":"18","author":"D Chen","year":"2024","journal-title":"China Typical Cases Book"},{"issue":"19","key":"pone.0324685.ref036","first-page":"100","article-title":"The value of cognitive-behavioral therapy in improving adverse emotions in schizophrenia patients","volume":"18","author":"F Peng","year":"2023","journal-title":"Psychol Monthly"},{"issue":"10","key":"pone.0324685.ref037","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1176\/appi.ajp.158.10.1706","article-title":"Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders","volume":"158","author":"C Barrowclough","year":"2001","journal-title":"Am J Psychiatry"},{"issue":"2","key":"pone.0324685.ref038","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"SR Kay","year":"1987","journal-title":"Schizophr Bull"},{"issue":"3","key":"pone.0324685.ref039","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40263-024-01151-7","article-title":"Negative symptoms in schizophrenia: an update on research assessment and the current and upcoming treatment landscape","volume":"39","author":"P Govil","year":"2025","journal-title":"CNS Drugs"},{"issue":"18","key":"pone.0324685.ref040","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e37763","article-title":"From theory to practice: revealing the real-world impact of cognitive behavioral therapy in psychological disorders through a dynamic bibliometric and survey study","volume":"10","author":"HD Hassan Kariri","year":"2024","journal-title":"Heliyon"},{"key":"pone.0324685.ref041","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.schres.2009.03.035","article-title":"Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis","volume":"113","author":"J Ventura","year":"2009","journal-title":"Schizophr Res"},{"key":"pone.0324685.ref042","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.schres.2011.04.014","article-title":"Disconnected and underproductive speech in schizophrenia: unique relationships across multiple indicators of social functioning","volume":"131","author":"CR Bowie","year":"2011","journal-title":"Schizophr Res"},{"issue":"5","key":"pone.0324685.ref043","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.euroneuro.2014.03.008","article-title":"Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment","volume":"24","author":"MJ Millan","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"pone.0324685.ref044","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/schbul\/sbn008","article-title":"Defeatist beliefs as a mediator of cognitive impairment, negative symptoms, and functioning in schizophrenia","volume":"35","author":"PM Grant","year":"2009","journal-title":"Schizophr Bull"},{"issue":"2","key":"pone.0324685.ref045","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1176\/appi.ajp.2012.12010109","article-title":"The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation","volume":"170","author":"AM Kring","year":"2013","journal-title":"Am J Psychiatry"},{"key":"pone.0324685.ref046","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.schres.2012.10.012","article-title":"Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale","volume":"142","author":"GP Strauss","year":"2012","journal-title":"Schizophr Res"},{"issue":"4","key":"pone.0324685.ref047","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/acps.12289","article-title":"Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia","volume":"130","author":"G Fervaha","year":"2014","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"pone.0324685.ref048","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1037\/a0037098","article-title":"Randomized clinical trial of cognitive behavioral social skills training for schizophrenia: improvement in functioning and experiential negative symptoms","volume":"82","author":"E Granholm","year":"2014","journal-title":"J Consult Clin Psychol"},{"issue":"6","key":"pone.0324685.ref049","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/schbul\/sbu033","article-title":"Feasibility, acceptability, and preliminary efficacy of a smartphone intervention for schizophrenia","volume":"40","author":"D Ben-Zeev","year":"2014","journal-title":"Schizophr Bull"},{"issue":"1","key":"pone.0324685.ref050","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.schres.2013.07.055","article-title":"Mindfulness interventions for psychosis: a meta-analysis","volume":"150","author":"B Khoury","year":"2013","journal-title":"Schizophr Res"},{"issue":"7","key":"pone.0324685.ref051","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1017\/S0033291714003110","article-title":"A systematic review and meta-analysis of exercise interventions in schizophrenia patients","volume":"45","author":"J Firth","year":"2015","journal-title":"Psychol Med"},{"issue":"3","key":"pone.0324685.ref052","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/wps.20458","article-title":"Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis","volume":"16","author":"D Vancampfort","year":"2017","journal-title":"World Psychiatry"},{"key":"pone.0324685.ref053","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.schres.2014.10.043","article-title":"Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later","volume":"161","author":"J Ventura","year":"2015","journal-title":"Schizophr Res"},{"issue":"3","key":"pone.0324685.ref054","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/schbul\/sbr026","article-title":"Divergent trajectories of physical, cognitive, and psychosocial aging in schizophrenia","volume":"37","author":"DV Jeste","year":"2011","journal-title":"Schizophr Bull"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0324685","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T17:58:35Z","timestamp":1747763915000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0324685"}},"subtitle":[],"editor":[{"given":"Carlos Eduardo","family":"Thomaz,","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":54,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0324685","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]}}}